Clinical Trial Update: Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity [Phase 3]

View source ↗

Summary

A phase 3 clinical trial update describing a protocol to shrink the anterior border of the CTV2 target volume in nasopharyngeal carcinoma to spare the nasal cav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Snippet

Sponsor: Hai-Qiang Mai,MD,PhD | Conditions: Nasopharyngeal Cancinoma (NPC) | Phase 3 | Status: NOT_YET_RECRUITING